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INTRODUCTION:  Pancreatic  VIPomas  are  exceedingly  rare,  with  an annual  incidence  of  less than  1 per
million.  Most  VIPomas  are  metastatic  at diagnosis,  with  the  liver  being  the most  common  site  of  spread.
PRESENTATION  OF  CASE:  We  describe  a highly  unusual  case  of  a metastatic  pancreatic  VIPoma  to an  ovary
in a 54 year-old  patient.  She  was ten  years  out from  her initial  diagnosis  when  routine  CT  scan  showed
an enlarging  left adnexal  mass.  After  having  both  ovaries  removed  laparoscopically  the  ﬁnal  pathology
was  consistent  with  her pancreatic  primary.  To  our  knowledge,  there  has  been  only  one  other  such  case
described  in  the  literature.
DISCUSSION:  In this  case,  pathology  revealed  metastatic  neuroendocrine  tumor  involving  both  the  left
and  right ovaries  despite  only  the  right ovary  apparently  enlarging.  In our  literature  search,  only  twoeuroendocrine tumors
NET
ancreatic cancer
other  cases  of  metastatic  PNET  to the  ovaries  have  been  reported.  One  case  was  a glucagonoma  and  the
other a VIPoma.  We  recommend  that  clinicians  consider  referral  of  patients  with  metastatic  NET and
ovarian  metastases  to  gynecologic  surgery  for consideration  of surgical  resection.
CONCLUSION:  In conclusion,  this  case  proves  that  although  uncommon,  PNET  can  show  metastases  in
both ovaries  even  a decade  after  initial  diagnosis.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Pancreatic neuroendocrine tumors (PNET) are rare neoplasms,
epresenting approximately 3–5% of all pancreatic malignancies.
hey are often classiﬁed as functional (hormone producing) or
onfunctional. Examples of functional PNETs include gastrino-
as, insulinomas, glucagonomas, somaostatinomas, or vasoactive
ntestinal peptide tumors (VIPomas) [2,3]. VIPomas are exceed-
ngly rare, with an annual incidence of less than 1 per million.
hey are characterized by severe watery diarrhea, often associated
ith electrolyte abnormalities such as hypokalemia and achlorhy-
ria. Most VIPomas are metastatic at diagnosis, with the liver being
he most common site of spread. In this case report, we  describe a
ighly unusual case of an isolated metastatic pancreatic VIPoma to
n ovary. To our knowledge, there has been only one other such case
escribed in the literature. This case demonstrates the importance
f pre-operative consideration of metastatic NET to the ovary.∗ Corresponding author.
E-mail address: Sachin.Apte@mofﬁtt.org (S.M. Apte).
ttp://dx.doi.org/10.1016/j.ijscr.2015.11.006
210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Presentation of case
A 54 year old female with no signiﬁcant past medical history
presented with 18 month history of diarrhea in August of 2004 and
was found to have profound dehydration with hypokalemia requir-
ing multiple hospital admissions. She had a markedly elevated VIP
level of 1299 pg/ml and was  placed on octreotide 500 micrograms
twice daily with symptom resolution. Pancreas protocol CT demon-
strated a mass in the tail of the pancreas with suspected liver
metastases. In October of 2004, she underwent distal pancreate-
ctomy, splenectomy, and radiofrequency ablation of multiple liver
metastases. Final pathology revealed well differentiated neuroen-
docrine tumor, with a proliferative index of 2–3%. She remained on
octreotide monotherapy until May  of 2011 when imaging showed
increasing size of liver metastases. She was  placed on capecitabine
and temozolomide achieving stable disease as best response after
9 cycles. She continued to be clinically stable on octreotide until
July 2014 when CT scans revealed progressive liver metastases
and a new left sided pelvic mass. The ovaries were further imaged
via pelvic US (Fig. 1). Somatostatin receptor scintigraphy revealed
somatostatin receptor expression in the liver and left ovary. She
was started on everolimus, but tolerated the drug poorly and dis-
continued it after one week and subsequently underwent two
additional bland hepatic artery embolizations. Due to enlarging left
ovarian metastasis as the only known site of viable disease, the
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Transvaginal ultrasound showing left sided adnexal mass.
Fig 2. Well-circumscribed nodular lesion with H&E at 20x magniﬁcation.
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Fig 4. Tumor cells with salt and pepper chromatic H&E at 200x magniﬁcation.Fig. 3. Tumor cell formation with H&E at 200x magniﬁcation.
atient underwent a laparoscopic bilateral salpingoophorectomy
n February of 2015 (Figs. 2 & 3 ).
. DiscussionMetastatic neuroendocrine tumors (NET) from the pancreas to
he ovary are extremely rare. We  identiﬁed two cases of PNET
etastatic to the ovary in the literature. The ﬁrst case involved apatient who  presented with a right ovarian mass ﬁve years after
resection of a glucagonoma involving the body and tail of the
pancreas [1]. The second case was a VIPoma in the body of the
pancreas along with somatostatin receptor scintigraphy revealing
a 1.8 cm right ovarian mass. This particular patient was  treated with
the somatostatin analogue octreotide only [4]. Although systemic
options for treatment of PNETs are expanding, surgical cytore-
duction remains an important treatment modality [5]. It should
also be mentioned that neuroendocrine tumors arising in different
anatomic sites share similar morphology and short-term outcomes
[5] as long as their grades are the same. Ovarian metastases from
neuroendocrine tumors can often enlarge even in the setting of
otherwise stable systemic disease (Fig. 4). The presence of bilat-
eral tumors and well-circumscribed nodular lesions (especially
when they are multiple) are in favor of metastatic disease in the
ovaries. In this case, pathology revealed metastatic neuroendocrine
tumor involving both the left and right ovaries consistent with
the patients known pancreatic primary NET despite only the right
ovary apparently enlarging. Consequently, we recommend that
clinicians consider referral of patients with metastatic NET and
ovarian metastases to gynecologic surgery for consideration of sur-
gical resection (Fig. 5). Removal of both ovaries is critical since
metastases are typically bilateral [6].
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cig. 5. Tumor with immunostain for synaptophysin positive at 100x magniﬁcation.
. Conclusion
The above case highlights that physicians should consider
etastatic NET in females with a pelvic mass or enlarging adnexa
nd a history of primary NET. NETs in general, and VIPomas in par-
icular, do not require as an aggressive surgical approach as primary
varian malignancies. Standard debulking, in the form of metas-
atectomy such as oophorectomy, would likely render patients as
o evidence of disease without a lymphadenectomy required of a
ebulking operation for primary ovarian cancer. As such, we cannot
tress the importance of considering the diagnosis pre-operatively
o allow for the best intraoperative decision pathway and informed
onsent.
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